ALK and non-small cell lung carcinoma: All methods of immunotherapy could be used in advanced NSCLC patients after excluding the presence of at least basic genetic abnormalities in the EGFR, ALK, and ROS1 genes since the low effectiveness of immunotherapy in such patients has been proven.